BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 596.52 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 129.81 % — a change of 359.53% (higher).

Cash Conversion

596.52 %

YoY

359.53%

Last updated:

Cash Conversion Rate (OCF/Net Income) of BrightGene Bio-Medical Technology Co is 2025 596.52 % . Cash Conversion Rate (OCF/Net Income) of BrightGene Bio-Medical Technology Co was 2024 129.81 % . It decreases by 359.53% higher compared to the previous year.

The BrightGene Bio-Medical Technology Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
87.41 CNY
Jan 1, 2019
55.21 CNY
Jan 1, 2020
91.49 CNY
Jan 1, 2021
72.18 CNY
Jan 1, 2022
129.90 CNY
Jan 1, 2023
96.20 CNY
Jan 1, 2024
129.81 CNY
Jan 1, 2025
596.52 CNY
The BrightGene Bio-Medical Technology Co Cash Conversion history
YEARCash ConversionYoY
596.52 %+359.53%
129.81 %+34.94%
96.20 %-25.94%
129.90 %+79.97%
72.18 %-21.11%
91.49 %+65.71%
55.21 %-36.84%
87.41 %+12.12%
77.96 %-55.26%
174.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Cash Conversion Rate (OCF/Net Income) of BrightGene Bio-Medical Technology Co is 596.52 % in 2025.

Cash Conversion Rate (OCF/Net Income) of BrightGene Bio-Medical Technology Co changed from 129.81 % to 596.52 %, representing a 359.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co